Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2011 1
2012 3
2013 4
2014 3
2015 3
2016 5
2017 7
2018 1
2019 1
2020 4
2021 7
2022 5
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of Vital Status, Cause of Death, and Follow-Up after Hematopoietic Cell Transplantation in Linked Center for International Blood and Marrow Transplant Research and California Cancer Registry Data, 1991 to 2018.
Valcarcel B, Schonfeld SJ, Meyer CL, Brunson A, Cooley JJP, Abrahão R, Wun T, Auletta JJ, Gadalla SM, Engels E, Albert PS, Spellman SR, Rizzo JD, Shaw BE, Muffly L, Keegan THM, Morton LM. Valcarcel B, et al. Transplant Cell Ther. 2024 Feb;30(2):239.e1-239.e11. doi: 10.1016/j.jtct.2023.11.011. Epub 2023 Nov 20. Transplant Cell Ther. 2024. PMID: 37981238
Linking the HCT database of the Center for International Blood and Marrow Transplant Research (CIBMTR) with cancer registry data may improve long-term outcome ascertainment, but the reliability of mortality data in death certificates from cancer registries among HCT recipi …
Linking the HCT database of the Center for International Blood and Marrow Transplant Research (CIBMTR) with cancer registry data may improve …
Large T-cell extradural lymphoma with concurrent marked cerebrospinal fluid eosinophilia in a dog.
Massie AM, Skorupski K, Vernau W, McLarty E, Brady RV, Vernau KM. Massie AM, et al. J Vet Intern Med. 2023 Nov-Dec;37(6):2492-2497. doi: 10.1111/jvim.16854. Epub 2023 Oct 17. J Vet Intern Med. 2023. PMID: 37849352 Free PMC article.
The dog was euthanized 39 months after presentation for multiorgan failure secondary to neutropenic sepsis and aspiration pneumonia. This represents a positive long-term response to multimodal treatment of extradural T-cell lymphoma within the vertebral canal associated wi …
The dog was euthanized 39 months after presentation for multiorgan failure secondary to neutropenic sepsis and aspiration pneumonia. This re …
A bio-instructive parylene-based conformal coating suppresses thrombosis and intimal hyperplasia of implantable vascular devices.
Hao D, Lin J, Liu R, Pivetti C, Yamashiro K, Schutzman LM, Sageshima J, Kwong M, Bahatyrevich N, Farmer DL, Humphries MD, Lam KS, Panitch A, Wang A. Hao D, et al. Bioact Mater. 2023 Jun 25;28:467-479. doi: 10.1016/j.bioactmat.2023.06.014. eCollection 2023 Oct. Bioact Mater. 2023. PMID: 37408799 Free PMC article.
This coating used a polyethylene glycol (PEG) linker to introduce an endothelial progenitor cell (EPC) specific binding ligand LXW7 (cGRGDdvc) onto the vascular devices for preventing platelet adhesion and selectively capturing endogenous EPCs. Also, we confirmed the long-term …
This coating used a polyethylene glycol (PEG) linker to introduce an endothelial progenitor cell (EPC) specific binding ligand LXW7 (cGRGDdv …
Current Smoking and Risk of Coronavirus Infection and Illness in a Highly Controlled Challenge Study: A Re-analysis of the British Cold Study.
Dove MS, Leistikow BN, Khan N, Tong EK. Dove MS, et al. Nicotine Tob Res. 2023 May 22;25(6):1198-1201. doi: 10.1093/ntr/ntac148. Nicotine Tob Res. 2023. PMID: 36194540 Free PMC article.
RESULTS: Current smokers had a higher adjusted risk than noncurrent smokers for infection (adjusted RR [aRR] = 1.12, 95% CI: 1.01, 1.25) and illness (aRR = 1.48, 95% CI: 1.11, 1.96). Neither association was modified by an interaction term for smoking and type of virus (inf …
RESULTS: Current smokers had a higher adjusted risk than noncurrent smokers for infection (adjusted RR [aRR] = 1.12, 95% CI: 1.01, 1.25) and …
Linking the Center for International Blood and Marrow Transplant Research Registry to the California Cancer Registry and California Hospital Patient Discharge Data.
Keegan THM, Brunson A, Cooley JJP, Schonfeld SJ, Meyer CL, Valcarcel B, Abrahao R, Wun T, Auletta J, Muffly L, Morton LM. Keegan THM, et al. Transplant Cell Ther. 2022 Dec;28(12):859.e1-859.e10. doi: 10.1016/j.jtct.2022.09.016. Epub 2022 Sep 27. Transplant Cell Ther. 2022. PMID: 36174935 Free PMC article.
Advances in hematopoietic cell transplantation (HCT) have substantially improved patient survival, increasing the importance of studying outcomes and long-term adverse effects in the rapidly growing population of HCT survivors. ...In this retrospective cohort study, probab …
Advances in hematopoietic cell transplantation (HCT) have substantially improved patient survival, increasing the importance of studying out …
Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403).
Mack PC, Miao J, Redman MW, Moon J, Goldberg SB, Herbst RS, Melnick MA, Walther Z, Hirsch FR, Politi K, Kelly K, Gandara DR. Mack PC, et al. Clin Cancer Res. 2022 Sep 1;28(17):3752-3760. doi: 10.1158/1078-0432.CCR-22-0741. Clin Cancer Res. 2022. PMID: 35713632 Free PMC article.
CONCLUSIONS: Plasma clearance of mutant EGFR ctDNA at 8 weeks was highly and significantly predictive of PFS and OS, outperforming RECIST response for predicting long-term benefit....
CONCLUSIONS: Plasma clearance of mutant EGFR ctDNA at 8 weeks was highly and significantly predictive of PFS and OS, outperforming RECIST re …
PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery.
Koc S, Lloyd MW, Grover JW, Xiao N, Seepo S, Subramanian SL, Ray M, Frech C, DiGiovanna J, Webster P, Neuhauser S, Srivastava A, Woo XY, Sanderson BJ, White B, Lott P, Dobrolecki LE, Dowst H; PDXNet Consortium; Evrard YA, Wallace TA, Moscow JA, Doroshow JH, Mitsiades N, Kaochar S, Pan CX, Chen MS, Carvajal-Carmona L, Welm AL, Welm BE, Lewis MT, Govindan R, Ding L, Li S, Herlyn M, Davies MA, Roth J, Meric-Bernstam F, Robinson PN, Bult CJ, Davis-Dusenbery B, Dean DA 2nd, Chuang JH. Koc S, et al. NAR Cancer. 2022 Apr 22;4(2):zcac014. doi: 10.1093/narcan/zcac014. eCollection 2022 Jun. NAR Cancer. 2022. PMID: 35475145 Free PMC article.
These models have 2134 associated sequencing files from 873 samples across 308 patients, which are hosted on the Cancer Genomics Cloud powered by Seven Bridges and the NCI Cancer Data Service for long-term storage and access with dbGaP permissions. The portal includes resu …
These models have 2134 associated sequencing files from 873 samples across 308 patients, which are hosted on the Cancer Genomics Cloud power …
Determinants of heritable gene silencing for KRAB-dCas9 + DNMT3 and Ezh2-dCas9 + DNMT3 hit-and-run epigenome editing.
O'Geen H, Tomkova M, Combs JA, Tilley EK, Segal DJ. O'Geen H, et al. Nucleic Acids Res. 2022 Apr 8;50(6):3239-3253. doi: 10.1093/nar/gkac123. Nucleic Acids Res. 2022. PMID: 35234927 Free PMC article.
We elucidated cis regulatory features that contribute to the differential stability of epigenetic reprogramming, such as the active transcription histone marks H3K36me3 and H3K27ac strongly correlating with resistance to short-term repression and resistance to long-term …
We elucidated cis regulatory features that contribute to the differential stability of epigenetic reprogramming, such as the active transcri …
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy.
SenGupta D, Brinson C, DeJesus E, Mills A, Shalit P, Guo S, Cai Y, Wallin JJ, Zhang L, Humeniuk R, Begley R, Geleziunas R, Mellors J, Wrin T, Jones N, Milush J, Ferre AL, Shacklett BL, Laird GM, Moldt B, Vendrame E, Brainard DM, Ramgopal M, Deeks SG. SenGupta D, et al. Sci Transl Med. 2021 Jun 23;13(599):eabg3071. doi: 10.1126/scitranslmed.abg3071. Sci Transl Med. 2021. PMID: 34162752 Clinical Trial.
Larger clinical studies will be necessary to assess the efficacy of vesatolimod-based combination therapies aimed at long-term control of HIV infection....
Larger clinical studies will be necessary to assess the efficacy of vesatolimod-based combination therapies aimed at long-term contro …
Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma.
Tuscano JM, Poh C, Kaesberg P, Luxardi G, Merleev A, Marusina A, Brunson A, Rosenberg A, Jonas B, Maverakis E. Tuscano JM, et al. Clin Cancer Res. 2021 Sep 1;27(17):4726-4736. doi: 10.1158/1078-0432.CCR-20-4622. Epub 2021 Jun 4. Clin Cancer Res. 2021. PMID: 34088724 Free PMC article.
PURPOSE: Rituximab and lenalidomide are effective for previously untreated and relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). However, long-term survival and predictive biomarkers are not well described. PATIENTS AND METHODS: We conducted two phase II open …
PURPOSE: Rituximab and lenalidomide are effective for previously untreated and relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL …
46 results